Posted by Michael Wonder on 28 Jul 2017
Eiger announces FDA fast track designation granted for pegylated interferon lambda in hepatitis delta virus infection
27 July 2017 - Eiger BioPharmaceuticals today announced that the U.S. FDA has granted fast track designation for pegylated interferon lambda 1a as a potential treatment for chronic hepatitis delta virus infection.
Eiger licensed worldwide rights to Lambda from Bristol-Myers Squibb in April 2016. Lambda has been administered in HBV / HCV clinical trials involving over 3,000 subjects. Lambda has not been approved for any indication.
